机构：[1]Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Department of Pediatric Hematology and Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China[2]Nanjing Children’s Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China[3]Tumor Hospital Affiliated to Tianjin Medicine University, Tianjin, China[4]Qilu Hospital Affiliated to Shandong University, Qingdao, Shandong, China[5]The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China[6]West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China[7]Chinese People’s Armed Police Force General Hospital, Beijing, China[8]The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China[9]The Fourth Hospital Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China河北医科大学第四医院[10]Xiangya Hospital Affiliated to Central South University, Changsha, Hunan, China[11]Qilu Children’s Hospital Affiliated to Shandong University, Qingdao, Shandong, China[12]Xi’an Jiaotong University First Affiliated Hospital, Xi’an, Shanxi, China[13]TianJin Children’s Hospital, Tianjin, China[14]Beijing Tongren Hospital, Beijing, China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[15]Kunming Children’s Hospital, Kunming, Yunnan, Chi
Here we investigated the establishment of multicenter cooperative treatment groups in China, as well as radiotherapy compliance and effectiveness among children with renal tumors. Medical records were reviewed for 316 children with renal tumors diagnosed by a multicenter cooperative group from 14 hospitals in China from 1998 to 2012. Median patient age was 29.5 months (range, 2-173 months old), and male-to-female ratio was 1.4:1. After a median follow-up of 22 months (range, 1-177 months), five-year event-free survival rates were 72% overall; 76.1% for favorable histology (251 cases); 59% for unfavorable histology (27 cases); and 91%, 75%, 71%, 53%, and 48.5%, respectively for Stages I, II, III, IV, and V. Following standardized criteria, radiation therapy was indicated for 153 patients, among whom five-year event-free survival was 72.8% for the 95 who received radiation and 24% for the 58 patients who did not. Our results are reasonable but can be further improved and show the feasibility of a multicenter cooperative group model for childhood renal tumor treatment in China. Radiation therapy is important for stage III and IV patients but remains difficult to implement in some parts of China. Government management departments and medical professionals must pay attention to this situation. This clinical trial is registered with ChiCTR-PRCH-14004372.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|3 区生物
小类|3 区生物工程与应用微生物3 区医学：研究与实验
最新[2023]版：
无
JCR分区：
出版当年[2013]版：
Q4BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ4MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q3BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ3MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Department of Pediatric Hematology and Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China
通讯作者：
推荐引用方式(GB/T 7714)：
Cai Jiaoyang,Pan Ci,Lu Qin,et al.Childhood Renal Tumor: A Report from a Chinese Children's Cancer Group[J].BIOMED RESEARCH INTERNATIONAL.2014,2014:doi:10.1155/2014/894341.
APA：
Cai, Jiaoyang,Pan, Ci,Lu, Qin,Yan, Jie,Ju, Xiuli...&Tang, Jingyan.(2014).Childhood Renal Tumor: A Report from a Chinese Children's Cancer Group.BIOMED RESEARCH INTERNATIONAL,2014,
MLA：
Cai, Jiaoyang,et al."Childhood Renal Tumor: A Report from a Chinese Children's Cancer Group".BIOMED RESEARCH INTERNATIONAL 2014.(2014)
